Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298531 | 0.92 | SMN1; SMN2 (0.61) | NPC1SMN1; SMN2ALDH1A1RAB9AMAPT | |
| SCHEMBL1628199 | 0.87 | LOXL2 (0.45) | LOXL2NPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13244594 | 0.86 | FABP7 (0.42) | LOXL2NPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL11938510 | 0.86 | LOXL2 (0.44) | LOXL2NPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5449158 | 0.86 | PTPN11 (0.44) | LOXL2NPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL23090473 | 0.84 | CA1 (0.44) | LOXL2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL31245947 | 0.84 | CA12 (0.44) | LOXL2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL14648434 | 0.84 | KMT2A (0.48) | SMN1; SMN2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL3722014 | 0.84 | RXRA (0.51) | NPC1SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL988267 | 0.83 | LOXL2 (0.58) | LOXL2NPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024193641-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | 上海超阳药业有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2006127559-A2 | INDICIA BEARING PACKAGE FOR A DELIERY SYSTEM COMPRISING AN EDIBLE COMPOSITION | CADBURY ADAMS USA LLC (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-0934065-B1 | NOVEL CRYPTOPHYCIN DERIVATIVES AS ANTI-NEOPLASTIC AGENTS | UNIV HAWAII (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6680311-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | ELI LILLY AND COMPANY | 2004-01-20 | — | — | US | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | LOXL2 4026/4885NPC1 518/4885SMN1; SMN2 4588/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | LOXL2 4582/4885NPC1 669/4885SMN1; SMN2 4148/4885 |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | LOXL2 1440/4885NPC1 137/4885SMN1; SMN2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.